Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $7.07 USD
Change Today +0.36 / 5.37%
Volume 52.2K
TNXP On Other Exchanges
As of 4:00 PM 11/25/15 All times are local (Market data is delayed by at least 15 minutes).

tonix pharmaceuticals holdin (TNXP) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/22/15 - $10.72
52 Week Low
10/1/15 - $5.05
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

tonix pharmaceuticals holdin (TNXP) Related Businessweek News

No Related Businessweek News Found

tonix pharmaceuticals holdin (TNXP) Details

Tonix Pharmaceuticals Holding Corp., a clinical-stage pharmaceutical company, focuses on the identification and development of pharmaceutical products for the disorders of central nervous system in the United States. The company develops TNX-102 SL, a sublingual tablet formulation, which is in Phase 3 clinical development stage for the treatment of fibromyalgia; and Phase 2 clinical development stage for the treatment of post-traumatic stress disorder. It is also involved in the development of TNX-201, an oral formulation of (R)-isometheptene mucate for the treatment of episodic tension-type headache, which is in Phase 2 clinical development stage. In addition, the company has a pipeline of various other product candidates, including TNX-301, a fixed dose combination drug product for the treatment of alcohol abuse and dependence. Tonix Pharmaceuticals Holding Corp. was founded in 2007 and is headquartered in New York, New York.

16 Employees
Last Reported Date: 02/27/15
Founded in 2007

tonix pharmaceuticals holdin (TNXP) Top Compensated Officers

Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: $541.9K
Chief Financial Officer and Treasurer
Total Annual Compensation: $413.3K
Chief Scientific Officer, Controller and Secr...
Total Annual Compensation: $261.7K
Compensation as of Fiscal Year 2014.

tonix pharmaceuticals holdin (TNXP) Key Developments

Tonix Pharmaceuticals Holding Corp. Presents Additional Results on Tonmya Demonstrating Improvements in Sleep, Pain, and Other Outcomes in Fibromyalgia

Tonix Pharmaceuticals Holding Corp. presented additional results from its completed 12-week, 205-patient Phase 2b BESTFIT clinical study of Tonmya (TNX-102 SL; cyclobenzaprine HCl sublingual tablets, 2.8 mg) for the treatment of fibromyalgia. Tonmya is designed for chronic daily use at bedtime to treat fibromyalgia. Tonmya is currently being evaluated in the 500-patient Phase 3 AFFIRM study in fibromyalgia. As accepted by the U.S. Food and Drug Administration, the primary outcome measure for this Phase 3 study is a pain responder analysis, defined as the proportion of patients who report at least a 30% reduction in pain from baseline at the end of the 12-week treatment period. Tonix expects to report top-line data from the AFFIRM trial in the third quarter of 2016. Of the 174 patients who completed the BESTFIT study, 172 were evaluable for the analyses described in this paragraph. Of these 172, 88 patients were treated with Tonmya, and 84 were treated with placebo. According to a tertile analysis of reported sleep quality improvement, the 54 of these 172 patients who reported the greatest improvement in sleep quality, or top sleep tertile, were examined in further detail. Of those in the Tonmya group, 36, or 41%, were in the top sleep tertile compared to 18 of the 84 patients, or 21%, in the placebo group. Of the 42 patients in the top sleep tertile who experienced at least a 30% improvement in their pain from baseline, 28, or 67%, had received Tonmya, compared to 14, or 33%, who had received placebo. In other analyses, the relationships between reported sleep quality and several standard measures of fibromyalgia were evaluated. According to each of the three different assessments of sleep quality used in BESTFIT, improvement in patient-reported sleep quality was found to significantly correlate with improvement in pain as well as broader measures of fibromyalgia symptoms and impact. These findings from BESTFIT may support the hypothesis that improving sleep quality facilitates pain improvement over time, and is consistent with the growing recognition of a reciprocal relationship between sleep and chronic, widespread pain. Nonrestorative sleep has been linked to altered processes in the brain that are thought to be responsible for certain fibromyalgia symptoms.

Tonix Pharmaceuticals Holding Corp. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2015

Tonix Pharmaceuticals Holding Corp. announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2015. For the quarter, the company announced operating loss of $13,280,000 compared to $7,434,000 for the same period a year ago. Net loss was $13,250,000 compared to $7,419,000 for the same period a year ago. Net loss per common share, basic and diluted was $0.72 compared to $0.71 for the same period a year ago. The higher net loss was primarily due to increased research and development expense for clinical studies and related research, as well as increased general and administrative expense to support these and other corporate development activities. For the nine months, the company announced operating loss of $34,760,000 compared to $18,652,000 for the same period a year ago. Net loss was $34,694,000 compared to $18,627,000 for the same period a year ago. Net loss per common share, basic and diluted was $2.15 compared to $1.92 for the same period a year ago. Cash used in operations was $30.6 million for the nine months ended September 30, 2015, as compared to $14.6 million for the nine months ended September 30, 2014.

Tonix Pharmaceuticals Holding Corp Presents at 14th Annual BIO Investor Forum, Oct-20-2015

Tonix Pharmaceuticals Holding Corp Presents at 14th Annual BIO Investor Forum, Oct-20-2015 . Venue: Parc 55 Hotel, San Francisco, California, United States.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TNXP:US $7.07 USD +0.36

TNXP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TNXP.
View Industry Companies

Industry Analysis


Industry Average

Valuation TNXP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 2.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact TONIX PHARMACEUTICALS HOLDIN, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at